Clinical_JJ Isolates_NNS of_IN Staphylococcus_NP aureus_NN with_IN Ribosomal_NP Mutations_NP Conferring_NP Resistance_NP to_TO Macrolides_NP Six_CD strains_NNS of_IN Staphylococcus_NP aureus_NN isolated_VBN from_IN cystic_JJ fibrosis_NN patients_NNS after_IN treatment_NN with_IN azithromycin_NN were_VBD cross-resistant_JJ to_TO azithromycin_NN and_CC erythromycin_NN ._SENT None_NN of_IN the_DT isolates_NNS contained_VBD erm_NN or_CC msr(A)_NN genes_NNS ,_, but_CC they_PP all_RB carried_VBD either_DT A2058G/U_NP or_CC A2059G_NP mutations_NNS within_IN the_DT rrl_NN genes_NNS ,_, with_IN a_DT majority_NN of_IN the_DT rRNA_NN copies_NNS bearing_VBG the_DT mutation_NN ._SENT One_CD strain_NN displayed_VBD an_DT additional_JJ mutation_NN in_IN the_DT rplV_NP gene_NN ,_, encoding_VBG the_DT L22_JJ ribosomal_JJ protein_NN ._SENT Emergence_NN of_IN resistance_NN to_TO macrolides_NNS in_IN staphylococci_NNS shortly_RB after_IN the_DT therapeutic_JJ use_NN of_IN erythromycin_NN has_VBZ been_VBN reported_VBN ._SENT In_IN most_JJS cases_NNS ,_, macrolide_NN resistance_NN in_IN clinical_JJ isolates_NNS of_IN staphylococci_NNS has_VBZ been_VBN linked_VBN to_TO target_VB site_NN alteration_NN due_JJ to_TO methylation_NN of_IN adenosine_NN 2058_CD (_( A2058_NP )_) of_IN 23S_JJ rRNA_NN within_IN the_DT large_JJ ribosomal_JJ subunit_NN ._SENT These_DT ribosomal_JJ methylases_NNS are_VBP encoded_VBN by_IN erm_NN genes_NNS ._SENT In_IN some_DT cases_NNS ,_, ABC_NP transporters_NNS encoded_VBN by_IN plasmid-borne_JJ msr(A)_NN genes_NNS cause_VBP active_JJ efflux_NN of_IN 14-member-ring_NN (_( erythromycin_NN ,_, clarithromycin_NP ,_, roxithromycin_NN ,_, and_CC dirithromycin_NN )_) or_CC 15-member-ring_NN (_( azithromycin_NN )_) macrolides_NNS ._SENT Rare_JJ staphylococcal_JJ strains_NNS have_VBP been_VBN reported_VBN to_TO produce_VB a_DT macrolide_NN phosphotransferase_NN which_WDT inactivates_VBZ some_DT of_IN these_DT antimicrobials_NNS ._SENT Overall_RB ,_, in_IN several_JJ survey_NN studies_NNS ,_, drug_NN efflux_NN and_CC ribosomal_JJ methylation_NN have_VBP been_VBN found_VBN to_TO be_VB responsible_JJ for_IN macrolide_NN resistance_NN in_IN all_DT of_IN the_DT strains_NNS studied_VBD ._SENT The_DT use_NN of_IN macrolides_NNS for_IN the_DT treatment_NN of_IN staphylococcal_JJ infections_NNS is_VBZ generally_RB limited_VBN to_TO uncomplicated_JJ soft_JJ tissue_NN infections_NNS ._SENT Recently_RB ,_, it_PP has_VBZ been_VBN inferred_VBN from_IN anti-inflammatory_JJ and_CC antiadhesion_NN effects_NNS of_IN macrolides_NNS observed_VBN in_IN vitro_NN that_IN these_DT antimicrobials_NNS may_MD have_VB a_DT favorable_JJ action_NN at_IN low_JJ concentrations_NNS for_IN treatment_NN of_IN Pseudomonas_NP aeruginosa_NP infections_NNS ._SENT These_DT indirect_JJ effects_NNS might_MD be_VB helpful_JJ in_IN the_DT case_NN of_IN cystic_JJ fibrosis_NN ,_, where_WRB the_DT major_JJ cause_NN of_IN morbidity_NN and_CC mortality_NN remains_VBZ respiratory_JJ disease_NN ,_, with_IN P._NP aeruginosa_NP as_IN the_DT most_JJS frequently_RB organism_NN isolated_VBN ,_, followed_VBN by_IN Staphylococcus_NP aureus_NN ._SENT We_PP report_VBP on_IN six_CD strains_NNS of_IN erythromycin-resistant_JJ S._NP aureus_NN ,_, isolated_VBN from_IN patients_NNS suffering_VBG from_IN cystic_JJ fibrosis_NN ,_, with_IN unusual_JJ mutations_NNS of_IN the_DT ribosomal_JJ target_NN of_IN macrolides_NNS ._SENT Among_IN 12_CD S._NP aureus_NN strains_NNS resistant_JJ to_TO erythromycin_NN and_CC isolated_VBN from_IN cystic_JJ fibrosis_NN patients_NNS ,_, 6_CD did_VBD not_RB contain_VB erm_NN or_CC msr(A)_NN genes_NNS as_RB determined_VBN by_IN PCR_NP ._SENT These_DT strains_NNS ,_, S._NP aureus_NN UCN13_NP ,_, UCN14_NP ,_, UCN15_NP ,_, UCN16_NP ,_, UCN17_JJ ,_, and_CC UCN18_NP ,_, were_VBD isolated_VBN at_IN the_DT hospitals_NNS of_IN Brest_NP and_CC Caen_NP ,_, France_NP ,_, from_IN the_DT sputa_NNS of_IN five_CD patients_NNS (_( S._NP aureus_NN UCN13_NP and_CC UCN14_NP were_VBD isolated_VBN from_IN the_DT same_JJ patient_NN )_) suffering_NN from_IN cystic_JJ fibrosis_NN who_WP were_VBD treated_VBN with_IN azithromycin_NN (_( 10_CD mg/kg/day_NN )_) for_IN a_DT minimum_NN of_IN 3_CD months_NNS and_CC a_DT maximum_NN of_IN 1_CD year_NN ._SENT The_DT strains_NNS were_VBD considered_VBN to_TO be_VB genetically_RB unrelated_JJ since_IN the_DT patterns_NNS of_IN SmaI-restricted_NP DNA_NP differed_VBD by_IN more_JJR than_IN three_CD fragments_NNS after_IN pulsed-field_JJ gel_NN electrophoresis_NN analysis_NN (_( data_NNS not_RB shown_VBN )_) ._SENT All_DT isolates_NNS were_VBD resistant_JJ to_TO erythromycin_NN as_IN determined_VBN by_IN the_DT disk_NN diffusion_NN technique_NN ._SENT Macrolide-susceptible_NP S._NP aureus_NN ATCC_NP 29213_CD was_VBD included_VBN as_IN a_DT control_NN ._SENT MICs_NNS of_IN antibiotics_NNS were_VBD determined_VBN by_IN the_DT agar_NN dilution_NN method_NN with_IN Mueller-Hinton_NP medium_NN ._SENT Dalfopristin_NP (_( RP54476_NP )_) ,_, erythromycin_NN ,_, quinupristin_NP (_( RP57669_NP )_) ,_, quinupristin-dalfopristin_NP ,_, pristinamycin_NN ,_, and_CC spiramycin_NN were_VBD from_IN Aventis_NP Pharma_NP (_( Romainville_NP ,_, France_NP )_) ,_, and_CC lincomycin_NN was_VBD from_IN Pharmacia-Upjohn_NP (_( Kalamazoo_NP ,_, Mich._NP )_) ._SENT As_RB mentioned_VBN above_RB ,_, no_DT rRNA_NN methylase_NN genes_NNS [_SYM erm(A)_JJ ,_, erm(B)_JJ ,_, and_CC erm(C)_NNS ]_SYM or_CC efflux_NN gene_NN [_SYM msr(A)_NN ]_SYM could_MD be_VB detected_VBN by_IN PCR_NP with_IN specific_JJ primers_NNS ._SENT Since_IN mutations_NNS in_IN genes_NNS coding_VBG for_IN L4_NP or_CC L22_NP ribosomal_JJ proteins_NNS or_CC in_IN domains_NNS II_NP and_CC V_CD of_IN 23S_JJ rRNA_NNS have_VBP been_VBN reported_VBN to_TO be_VB responsible_JJ for_IN macrolide_NN resistance_NN in_IN a_DT variety_NN of_IN bacterial_JJ species_NNS ,_, we_PP hypothesized_VBD that_IN similar_JJ mutations_NNS might_MD account_VB for_IN resistance_NN in_IN the_DT strains_NNS studied_VBD ._SENT Portions_NNS of_IN rrl_NN genes_NNS for_IN domains_NNS II_NP and_CC V_CD of_IN 23S_JJ rRNA_NN and_CC the_DT genes_NNS for_IN ribosomal_JJ proteins_NNS L4_NP and_CC L22_NP were_VBD amplified_VBN by_IN PCR_NP from_IN total_JJ genomic_JJ DNA_NN with_IN the_DT oligonucleotides_NNS shown_VBN in_IN Table_NP ._SENT The_DT amplification_NN primers_NNS were_VBD designed_VBN after_IN analysis_NN of_IN the_DT sequence_NN of_IN S._NP aureus_NN COL_NN obtained_VBN from_IN The_DT Institute_NP for_IN Genomic_NP Research_NP website_NN ._SENT Mutations_NNS were_VBD screened_VBN for_IN by_IN PCR-SSCP_NP ,_, as_RB described_VBN previously_RB ._SENT After_IN heat_NN denaturation_NN ,_, the_DT single-stranded_JJ PCR_NP products_NNS were_VBD separated_VBN by_IN nondenaturing_JJ polyacrylamide_NN gel_NN electrophoresis_NN ._SENT Fragments_NNS with_IN mobilities_NNS different_JJ from_IN those_DT of_IN susceptible_JJ controls_NNS were_VBD sequenced_JJ ._SENT We_PP also_RB determined_VBD the_DT copy_NN numbers_NNS of_IN the_DT rrl_NN genes_NNS carrying_VBG 23S_JJ rRNA_NN mutations_NNS ._SENT A_DT strategy_NN was_VBD developed_VBN to_TO amplify_VB the_DT different_JJ copies_NNS of_IN rrl_NN domain_NN V_NN individually_RB ._SENT Sequence_NN analysis_NN of_IN S._NP aureus_NN COL_NP showed_VBD that_IN the_DT strain_NN carried_VBD six_CD copies_NNS of_IN the_DT rrl_NN gene_NN ._SENT We_PP used_VBD primers_NNS complementary_JJ to_TO unique_JJ sequences_NNS downstream_JJ from_IN each_DT rrl_NN gene_NN (_( V_CD LA_NP to_TO V_CD LF_NP in_IN Table_NP )_) and_CC a_DT primer_NN common_JJ to_TO the_DT six_CD alleles_NNS and_CC complementary_JJ to_TO a_DT region_NN upstream_RB from_IN the_DT peptidyl_NN transferase_NN region_NN in_IN domain_NN V_CD (_( V_CD U1_NN )_) ._SENT Internal_JJ primers_NNS (_( V_CD U2_NP and_CC V_CD L2_NN )_) were_VBD then_RB used_VBN to_TO amplify_VB a_DT 144-bp_JJ fragment_NN encompassing_VBG the_DT domain_NN V_CD region_NN ,_, which_WDT was_VBD subsequently_RB sequenced_JJ ._SENT TABLE_NN 1_CD |_SYM Oligodeoxynucleotides_NP used_VBN for_IN the_DT amplification_NN of_IN fragments_NNS of_IN the_DT 23S_JJ rRNA_NN gene_NN and_CC of_IN ribosomal_JJ protein_NN genes_NNS The_DT six_CD isolates_NNS were_VBD highly_RB resistant_JJ to_TO erythromycin_NN and_CC azithromycin_NN (_( MIC_JJ of_IN >128_JJ mug/ml_NN )_) ._SENT Five_CD strains_NNS were_VBD also_RB resistant_JJ to_TO the_DT 16-member-ring_NN macrolide_NN spiramycin_NN ,_, whereas_IN the_DT spiramycin_NN MIC_NN for_IN strain_NN UCN16_NN was_VBD lower_JJR (_( 8_CD mug/ml_NN )_) ._SENT MICs_NNS of_IN quinupristin_NP ,_, a_DT streptogramin_NP B_NP ,_, and_CC clindamycin_NN were_VBD more_JJR widely_RB distributed_VBN ._SENT MICs_NNS of_IN dalfopristin_NP ,_, a_DT streptogramin_NP A_NP ,_, were_VBD similar_JJ to_TO those_DT for_IN susceptible_JJ strains_NNS ._SENT All_DT strains_NNS except_IN strain_NN UCN15_NP were_VBD susceptible_JJ to_TO quinupristin-dalfopristin_NN and_CC pristinamycin_NN ._SENT TABLE_NN 2_CD |_SYM MICs_NN of_IN macrolides_NNS ,_, lincosamides_NNS ,_, and_CC streptogramins_NNS Sequencing_NN showed_VBD that_IN SSCP_NP mobilities_NNS of_IN fragments_NNS different_JJ from_IN those_DT of_IN the_DT controls_NNS amplified_VBN from_IN S._NP aureus_NN ATCC_NP 29213_CD were_VBD associated_VBN with_IN point_NN mutations_NNS or_CC a_DT deletion_NN ._SENT Four_CD strains_NNS ,_, S._NP aureus_NN UCN13_NP ,_, UCN15_NP ,_, UCN16_NP ,_, and_CC UCN17_JJ ,_, carried_VBD an_DT A2058G_NP (_( E._NP coli_NNS numbering_VBG )_) transition_NN ;_: S._NP aureus_NN UCN14_NP contained_VBD an_DT A2058T_NP transversion_NN ;_: and_CC S.aureus_NP UCN18_NP had_VBD an_DT A2059G_NP transition_NN ._SENT No_DT mutation_NN was_VBD detected_VBN in_IN domain_NN II_NP of_IN 23S_JJ rRNA_NN or_CC in_IN the_DT rplD_NN gene_NN (_( encoding_VBG the_DT L4_NP protein_NN )_) ._SENT In_IN strain_NN UCN15_NP ,_, a_DT deletion_NN of_IN nine_CD nucleotides_NNS which_WDT would_MD result_VB in_IN the_DT deletion_NN of_IN three_CD amino_NN acids_NNS at_IN position_NN 101_CD of_IN the_DT deduced_VBN amino_NN acid_NN sequence_NN of_IN protein_NN L22_NP was_VBD associated_VBN with_IN the_DT A2058G_NP mutation_NN ._SENT Mutations_NNS at_IN positions_NNS A2058_NP and_CC A2059_NP were_VBD associated_VBN with_IN macrolide-lincosamide-streptogramin_NN B_NN and_CC macrolide-lincosamide_NN phenotypes_NNS ,_, respectively_RB ,_, similar_JJ to_TO those_DT already_RB reported_VBN for_IN other_JJ organisms_NNS ._SENT Relative_JJ to_TO other_JJ rRNA_NN mutations_NNS ,_, A2058G_NP gives_VBZ the_DT highest_JJS level_NN of_IN resistance_NN to_TO 14-member-ring_NN macrolides_NNS and_CC confers_VBZ macrolide-lincosamide-streptogramin_NN B_NN resistance_NN ,_, defined_VBN as_IN high_JJ resistance_NN to_TO all_DT of_IN the_DT antimicrobials_NNS in_IN this_DT group_NN ._SENT However_RB ,_, MICs_NNS of_IN clindamycin_NN and_CC quinupristin_NN were_VBD lower_JJR than_IN expected_VBN for_IN strains_NNS UCN14_NP ,_, UCN15_NP ,_, UCN16_NP ,_, and_CC UCN18_NP ._SENT This_DT might_MD be_VB due_JJ to_TO the_DT fact_NN that_IN these_DT staphylococci_NNS grew_VBD slowly_RB on_IN agar_NN ,_, as_RB has_VBZ been_VBN reported_VBN for_IN most_JJS S._NP aureus_NN strains_NNS isolated_VBN from_IN cystic_JJ fibrosis_NN patients_NNS ,_, which_WDT frequently_RB yield_VBP small-colony_JJ variants_NNS ._SENT The_DT A-to-U_NP or_CC A-to-G_NP substitutions_NNS gave_VBD a_DT similar_JJ level_NN of_IN resistance_NN ._SENT The_DT A2059_NP mutation_NN gave_VBD the_DT macrolide-lincosamide_NN phenotype_NN ,_, with_IN moderate_JJ resistance_NN to_TO clindamycin_NN and_CC no_DT resistance_NN to_TO streptogramins_NP B_NP ,_, as_RB previously_RB reported_VBN for_IN Helicobacter_NP pylori_NNS and_CC Streptococcus_NN pneumoniae_NNS ._SENT Resistance_NN by_IN mutation_NN in_IN 23S_JJ rRNA_NN has_VBZ generally_RB been_VBN reported_VBN for_IN bacteria_NNS with_IN few_JJ copies_NNS of_IN rrn_NN operons_NNS ,_, such_JJ as_IN H._NP pylori_NNS ,_, Mycoplasma_NP pneumoniae_NNS ,_, Mycobacterium_NN intracellulare_NN ,_, and_CC Mycobacterium_NN avium_NN ._SENT However_RB ,_, mutations_NNS in_IN 23S_JJ rRNA_NNS have_VBP been_VBN reported_VBN for_IN S._NP pneumoniae_NNS ,_, which_WDT contains_VBZ four_CD rrn_NN operons_NNS ._SENT In_IN PCR_NP experiments_NNS carried_VBD out_RP to_TO determine_VB the_DT copy_NN numbers_NNS of_IN mutated_VBN rrl_NN genes_NNS ,_, one_CD copy_NN ,_, named_VBN B_NP ,_, could_MD not_RB be_VB amplified_VBN from_IN five_CD of_IN our_PP$ strains_NNS ._SENT In_IN silico_NN analysis_NN of_IN strain_NN N315_NP DNA_NP ,_, available_JJ at_IN the_DT National_NP Center_NP for_IN Biotechnology_NP Information_NP website_NN ,_, revealed_VBD that_IN it_PP also_RB contained_VBD only_RB five_CD rrl_NN copies_NNS and_CC that_IN the_DT copy_NN at_IN a_DT position_NN similar_JJ to_TO that_DT of_IN the_DT B_NP copy_NN was_VBD missing_VBG ._SENT In_IN every_DT erythromycin-resistant_JJ strain_NN ,_, three_CD or_CC four_CD copies_NNS were_VBD mutated_VBN ,_, confirming_VBG that_DT mutation_NN in_IN a_DT majority_NN of_IN rrl_NN operons_NNS was_VBD associated_VBN with_IN significant_JJ resistance_NN ,_, as_RB reported_VBN for_IN S._NP pneumoniae_NNS ._SENT Resistance_NN to_TO streptogramins_NNS was_VBD observed_VBN in_IN strain_NN UCN15_NP ,_, which_WDT combined_VBD a_DT rplV_NN mutation_NN with_IN an_DT A2058G_NP mutation_NN ._SENT Recently_RB ,_, resistance_NN to_TO quinupristin-dalfopristin_NN in_IN staphylococcal_JJ strains_NNS selected_VBN under_IN treatment_NN with_IN this_DT antibiotic_NN has_VBZ been_VBN explained_VBN by_IN similar_JJ mutations_NNS in_IN the_DT conserved_VBN 3_CD '_POS end_NN of_IN the_DT rplV_NP gene_NN )_) ._SENT Isolation_NN of_IN staphylococci_NNS with_IN resistance_NN to_TO macrolides_NNS conferred_VBN by_IN ribosomal_JJ mutations_NNS is_VBZ unusual_JJ ._SENT It_PP may_MD be_VB related_VBN to_TO the_DT specific_JJ context_NN of_IN cystic_JJ fibrosis_NN ._SENT Half_NN of_IN 12_CD erythromycin-resistant_JJ strains_NNS of_IN S._NP aureus_NN isolated_VBN from_IN cystic_JJ fibrosis_NN patients_NNS in_IN our_PP$ institutions_NNS were_VBD mutants_NNS ._SENT Indeed_RB ,_, patients_NNS suffering_VBG from_IN this_DT genetic_JJ disorder_NN receive_VB multiple_JJ courses_NNS of_IN antibiotics_NNS ._SENT In_IN addition_NN ,_, administration_NN of_IN macrolides_NNS at_IN low_JJ doses_NNS aimed_VBN at_IN preventing_VBG Pseudomonas_NP infections_NNS might_MD favor_VB the_DT emergence_NN of_IN mutants_NNS ,_, although_IN no_DT definitive_JJ relationship_NN could_MD be_VB proven_VBN in_IN this_DT study_NN ._SENT Finally_RB ,_, colonization_NN of_IN cystic_JJ fibrosis_NN patients_NNS by_IN hypermutable_JJ strains_NNS of_IN P._NP aeruginosa_NP has_VBZ been_VBN reported_VBN ._SENT A_DT similar_JJ possibility_NN for_IN the_DT staphylococcal_JJ isolates_NNS is_VBZ currently_RB under_IN investigation_NN ._SENT TABLE_NN 3_CD |_SYM Mutations_NNS of_IN the_DT rrl_NN genes_NNS 